{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:27:31Z","timestamp":1793460451041,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T00:00:00Z","timestamp":1728172800000},"content-version":"am","delay-in-days":340,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-17-1-0078"],"award-info":[{"award-number":["W81XWH-17-1-0078"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ygyno.2023.09.014","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T18:20:15Z","timestamp":1696616415000},"page":"69-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Targeting RAS-ERK pathway alterations with MEK inhibitors to improve chemosensitivity in high grade serous ovarian cancers"],"prefix":"10.1016","volume":"178","author":[{"given":"Nancy T.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Raetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Montoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caili","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Leiserowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2023.09.014_bb0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.humpath.2018.06.018","article-title":"Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics","author":"Prat","year":"2018","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ygyno.2023.09.014_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ajco.12449","article-title":"Frontline treatment of epithelial ovarian cancer","volume":"11","author":"Goh","year":"2015","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.09.014_bb0015","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.19.00194","article-title":"Management of platinum-resistent relapsed epithelial ovarian cancer and new drug perspectives","volume":"27","author":"Pujade-Lauraine","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.09.014_bb0020","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1111\/bph.15420","article-title":"The importance of Ras in drug resistance in cancer","volume":"179","author":"Healy","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ygyno.2023.09.014_bb0025","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3390\/ijms21031102","article-title":"Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity","volume":"21","author":"Lee","year":"2020","journal-title":"Int. J. Mol. Sc."},{"key":"10.1016\/j.ygyno.2023.09.014_bb0030","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fonc.2014.00034","article-title":"Reversing platinum resistance in high grade serous ovarian carcinoma: targeting BRCA and the homologous recombination system","volume":"4","author":"Wiedemeyer","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ygyno.2023.09.014_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.celrep.2020.107762","article-title":"Patient-derived ovarian cancer organoids mimic clinical response and exhibit Heterogenous inter- and intrapatient drug response","volume":"31","author":"De Witte","year":"2020","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.ygyno.2023.09.014_bb0040","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ygyno.2020.03.026","article-title":"Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma","volume":"157","author":"Chen","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.09.014_bb0045","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/nprot.2006.179","article-title":"Solforhodamine B coloimetric assay for cytotoxicity screening. National Center for genetics engineering and biotechnology","volume":"1","author":"Vichai","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ygyno.2023.09.014_bb0050","doi-asserted-by":"crossref","DOI":"10.7150\/thno.25613","article-title":"Distinct immune signatures in directly treated and distant tumors result from TLR adjuvants and focal ablation","volume":"8","author":"Chavez","year":"2018","journal-title":"Theranostics."},{"issue":"1","key":"10.1016\/j.ygyno.2023.09.014_bb0055","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrasfast universal RNA \u2013 seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics."},{"issue":"12","key":"10.1016\/j.ygyno.2023.09.014_bb0060","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"issue":"1","key":"10.1016\/j.ygyno.2023.09.014_bb0065","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","article-title":"Metascape provies a biologist-oriented resource for the analysis of systems-level datasets","volume":"10","author":"Zhou","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2023.09.014_bb0070","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","article-title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian (GOG 281\/LOGS): an international, randomized, open-label multicentr, phase 2\/3 trial","volume":"399","author":"Gershenson","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2023.09.014_bb0075","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ygyno.2014.01.008","article-title":"MEK 1\/2 inhibitors in the treatment of gynecologic malignancies","volume":"133","author":"Miller","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.09.014_bb0080","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2023.09.014_bb0085","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/sj.bjc.6602447","article-title":"Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cell lines","volume":"92","author":"Roberts","year":"2005","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2023.09.014_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001789","article-title":"Spatial and temporal heterogeneity in high grade serous ovarian cancer: a phylogenetic analysis","volume":"12","author":"Schwarz","year":"2015","journal-title":"PLoS Med."},{"key":"10.1016\/j.ygyno.2023.09.014_bb0095","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.gore.2018.01.005","article-title":"Clonal lineage of high grade serous cancers in a patient with neurofibromatosis 1","volume":"23","author":"Norris","year":"2018","journal-title":"Gynecol. Oncol. Reports."},{"issue":"9","key":"10.1016\/j.ygyno.2023.09.014_bb0100","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41588-018-0179-8","article-title":"Copy number signatures and mutational processes in ovarian carcinoma","volume":"50","author":"Macintyre","year":"2018","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ygyno.2023.09.014_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.celrep.2020.03.066","article-title":"Molecular analysis of clinically defined subsets of high-grade serous ovarian cancer","volume":"31","author":"Lee","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.ygyno.2023.09.014_bb0110","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1593\/neo.08784","article-title":"Neurofibromin 1 defects are common in human ovarian serous and co-occur with TP53 mutations","volume":"12","author":"Sangha","year":"2008","journal-title":"Neoplasia."},{"key":"10.1016\/j.ygyno.2023.09.014_bb0115","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analysis of ovarian carcinoma","volume":"474","author":"The Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature."},{"key":"10.1016\/j.ygyno.2023.09.014_bb0125","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.semcancer.2017.11.018","article-title":"The FOXO3-FOXM1 axis: a key cancer drug target and a modulator of cancer drug resistance","volume":"50","author":"Yao","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ygyno.2023.09.014_bb0130","doi-asserted-by":"crossref","first-page":"9974","DOI":"10.1073\/pnas.1732638100","article-title":"Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression","volume":"100","author":"Karlsson","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2023.09.014_bb0135","series-title":"FOXM1: An emerging master regulator of DNA damage response and genotoxic agent resistance","first-page":"1316","volume":"11","author":"Zona","year":"2014"},{"key":"10.1016\/j.ygyno.2023.09.014_bb0140","doi-asserted-by":"crossref","first-page":"11365","DOI":"10.18632\/oncotarget.2497","article-title":"Targeting of mutant p53-inducted FoxM1 with thiosterpton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells","volume":"5","author":"Zhang","year":"2014","journal-title":"Oncotarget."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823014865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823014865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:05:15Z","timestamp":1758773115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825823014865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":27,"alternative-id":["S0090825823014865"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.09.014","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting RAS-ERK pathway alterations with MEK inhibitors to improve chemosensitivity in high grade serous ovarian cancers","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}